D
Domenica Lorusso
Researcher at Agostino Gemelli University Polyclinic
Publications - 85
Citations - 5921
Domenica Lorusso is an academic researcher from Agostino Gemelli University Polyclinic. The author has contributed to research in topics: Ovarian cancer & Population. The author has an hindex of 15, co-authored 85 publications receiving 2791 citations. Previous affiliations of Domenica Lorusso include University of Milan & McGill University Health Centre.
Papers
More filters
Journal ArticleDOI
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W Holloway,Margarita Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,Deborah K. Armstrong,Jesus Garcia-Donas,Elizabeth M. Swisher,Anne Floquet,Gottfried E. Konecny,Iain A. McNeish,Clare L. Scott,Terri Cameron,Lara Maloney,Jeff Isaacson,Sandra Goble,Caroline Grace,Thomas Harding,Mitch Raponi,James Sun,Kevin K. Lin,Heidi Giordano,Jonathan A. Ledermann,Martin Buck,A Dean,Michael Friedlander,J C Goh,Paul R. Harnett,G Kichenadasse,C L Scott,H Denys,Luc Dirix,Ignace Vergote,Laurie Elit,Prafull Ghatage,Amit M. Oza,Marie Plante,Diane Provencher,J I Weberpals,Stephen Welch,A Floquet,Laurence Gladieff,Florence Joly,A Leary,Alain Lortholary,Jean-Pierre Lotz,J. Medioni,Olivier Tredan,Benoit You,A El-Balat,C Hänle,P Krabisch,T Neunhöffer,M Pölcher,Pauline Wimberger,Amnon Amit,S Kovel,M Leviov,Tamar Safra,Ronnie Shapira-Frommer,Salomon M. Stemmer,Alessandra Bologna,N Colombo,Domenica Lorusso,Sandro Pignata,Roberto Sabbatini,G Scambia,Stefano Tamberi,Claudio Zamagni,P C Fong,A O'Donnell,M Amenedo Gancedo,A Casado Herraez,J Garcia-Donas,E M Guerra,A Oaknin,I Palacio,Iris L. Romero,A Sanchez,Susana Banerjee,A Clamp,Y Drew,Hani Gabra,D Jackson,Jonathan A. Ledermann,I A McNeish,Christine Parkinson,Melanie E Powell,C Aghajanian,D K Armstrong,Michael J. Birrer,Mary K. Buss,Setsuko K. Chambers,L-m Chen,Robert L. Coleman,R W Holloway,G E Konecny,L Ma,Mark A. Morgan,R T Morris,David G. Mutch,D M O'Malley,B M Slomovitz,E M Swisher,T Vanderkwaak,M Vulfovich +116 more
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martín,Bhavana Pothuri,Ignace Vergote,René dePont Christensen,Whitney Graybill,Mansoor Raza Mirza,C McCormick,Domenica Lorusso,Paul Hoskins,Gilles Freyer,Klaus Baumann,K. Jardon,Andrés Redondo,Richard G. Moore,Christof Vulsteke,Roisin E. O'Cearbhaill,Bente Lund,Floor J. Backes,Pilar Barretina-Ginesta,Ashley Haggerty,Maria J. Rubio-Pérez,Mark S. Shahin,Giorgia Mangili,William H. Bradley,Ilan Bruchim,Kaiming Sun,I Malinowska,Y. Li,Divya Gupta,Bradley J. Monk,Engot-Ov,Gog Investigators +31 more
TL;DR: Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly longer progression-free survival thanThose who received placebo, regardless of the presence or absence of homologous-recombination deficiency.
Journal ArticleDOI
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard,Patricia Pautier,Sandro Pignata,David Pérol,Antonio González-Martín,Regina Berger,Keiichi Fujiwara,Ignace Vergote,Nicoletta Colombo,J. Maenpaa,Frédéric Selle,Jalid Sehouli,Domenica Lorusso,Eva Guerra Alia,Alexander Reinthaller,Shoji Nagao,C. Lefeuvre-Plesse,Ulrich Canzler,Giovanni Scambia,Alain Lortholary,Frederik Marmé,Pierre Combe,Nikolaus de Gregorio,Manuel Rodrigues,Paul Buderath,Coraline Dubot,Alexander Burges,Benoit You,Eric Pujade-Lauraine,Philipp Harter +29 more
TL;DR: In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance olaparib provided a significant progression-free survival benefit, which was substantial in patients with HRD-positive tumors, including those without a BRCA mutation.
Journal ArticleDOI
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Nicoletta Colombo,Cristiana Sessa,A. du Bois,Jonathan A. Ledermann,WG McCluggage,Iain A. McNeish,P. Morice,Sandro Pignata,Isabelle Ray-Coquard,Ignace Vergote,Thaïs Baert,I. Belaroussi,A. Dashora,Siel Olbrecht,François Planchamp,Denis Querleu,Susana Banerjee,P. Blecharz,Ilan Bruchim,David Cibula,Nicole Concin,Ben Davidson,Mojgan Devouassoux-Shisheboran,Annamaria Ferrero,R.M. Glasspool,Antonio González-Martín,Viola Heinzelmann-Schwarz,Florence Joly,J. W. Kim,Frédéric Kridelka,Domenica Lorusso,Sven Mahner,Mikio Mikami,Mansoor Raza Mirza,Shibani Nicum,Dearbhaile M. O'Donnell,Patricia Pautier,Alexandros Rodolakis,Jalid Sehouli,Fatih Selcukbiricik,Naveena Singh,David S.P. Tan,Dirk Timmerman,Germana Tognon,J. van der Velden,Petronella O. Witteveen,AG Zeimet +46 more
TL;DR: The recommendations presented here are based on the best available evidence and expert agreement and are presented with a summary of evidence supporting each recommendation.
Journal ArticleDOI
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
Nicole Concin,Xavier Matias-Guiu,Ignace Vergote,David Cibula,Mansoor Raza Mirza,Simone Marnitz,Jonathan A. Ledermann,Tjalling Bosse,Cyrus Chargari,Anna Fagotti,Christina Fotopoulou,Antonio Gonzalez Martin,Sigurd Lax,Domenica Lorusso,Christian Marth,Philippe Morice,Remi A. Nout,Dearbhaile M. O'Donnell,Denis Querleu,Maria Rosaria Raspollini,Jalid Sehouli,Alina Sturdza,Alexandra Taylor,Anneke M. Westermann,Pauline Wimberger,Nicoletta Colombo,François Planchamp,Carien L. Creutzberg +27 more
TL;DR: A European consensus conference on endometrial carcinoma was held in 2014 to produce multi-disciplinary evidence-based guidelines on selected questions as mentioned in this paper, and the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncologies (ESTRO), and the EPSP jointly decided to update these evidence-base guidelines and to cover new topics in order to improve the quality of care for women with endometrium carcinoma across Europe and worldwide.